Pacific Edge’s American dream

Pacific Edge’s American dream
The US Affordable Care Act can be tricky to navigate. (Image: Getty)
Paul McBeth
Pacific Edge has long wanted to crack the United States market, which it has seen for a long time as validating the hundreds of millions spent in developing its Cxbladder non-invasive cancer detection tool. More than 20 years since listing, after it was spun out of University of Otago research, the company has raised $297.23 million selling shares and convertible preference shares and as people exercised options to fund accumulated losses of $216.8m and counting. That’s not going to change any time soon after the company crashed...

More Markets

NZ sharemaket up 0.1% despite 'volatile' markets
Markets Market Close

NZ sharemaket up 0.1% despite 'volatile' markets

The S&P/NZX 50 Index closed at 12,338.57, up 18.38 points or 0.15%.

Graham Skellern 03 Apr 2025
NZX-listed companies take stock in wake of US tariff moves
Economy

NZX-listed companies take stock in wake of US tariff moves

Wine makers, manufacturers and others mull what trade wars will bring.

Ian Llewellyn 03 Apr 2025
Analysts struggle to find upside from Trump tariffs
Economy

Analysts struggle to find upside from Trump tariffs

‘They've forgotten the lessons of the Great Depression,’ one analyst said.

Gregor Thompson 03 Apr 2025
S&P/ASX200 takes a tumble on Trump's Liberation Day, Asia to follow suit
Markets

S&P/ASX200 takes a tumble on Trump's Liberation Day, Asia to follow suit

The fall may be short lived now there is more certainty. 

Rebecca Howard 03 Apr 2025